Taken together, our findings, including the IHC pattern, demonstrated that SLC16A1 and SLC16A3 could be potentially ideal prognosis makers and therapy targets for patients with pancreatic cancer as treatment strategies. The gene discussed is SLC16A3; the disease is familial pancreatic carcinoma.